… From our observation, CMVR lesion stopped in 2-4 weeks after induction with systemic
ganciclovir. Therefore, in our regimen, the standard induction with intravenous ganciclovir was …

… The development of ganciclovir's prodrug, valganciclovir, … of valganciclovir for treatment for
CMV disease we designed an … Children and patients with life-threatening CMV disease were …

… Since 1989, intravenous ganciclovir has been the backbone for treatment of CMV disease
[1,2]. Valganciclovir, an oral formulation of ganciclovir approved in 2001, allows for an oral …

… In transplantation, foscarnet is reserved for CMV diseases that are resistant or refractory
to ganciclovir. Such “alternate” role of foscarnet is due to common occurrence of renal …

… CMV disease in nine SOT recipients. … Cytomegalovirus infection was defined as a positive
CMV-specific assay in the absence of clinical symptoms, and CMV disease as a positive CMV …

… because the use of IV ganciclovir has been shown to be more beneficial than oral ganciclovir
36 due to its increased bioavailability; hence when giving ganciclovir IV one can expect an …

… The effect of cytomegalovirus (CMV) reactivation on the length of mechanical ventilation and
… intravenous ganciclovir increases the number of ventilator-free days in patients with CMV …

… The pharmacological management of CMV infection and reactivation in SOT recipients to
prevent CMV disease include the use of the antivirals ganciclovir (GCV) and the oral prodrug …

… Topical ganciclovir 0.15 % gel was first made available at our centre in March 2010. We …
the disease course of each eye inflicted with CMV anterior uveitis before and after ganciclovir …

… admission) or intravenous placebo every 12 hours. After 5 days, the dose was reduced to
5 mg/kg of intravenous ganciclovir or intravenous placebo once daily. Ganciclovir doses were …